📊 BIAFW Key Takeaways
Is bioAffinity Technologies, Inc. (BIAFW) a Good Investment?
bioAffinity Technologies exhibits severe financial distress with collapsing revenues (-34.2% YoY), massive operating losses (-10.6M on 6.2M revenue), and negative cash flow (-9.4M FCF). The company is burning cash rapidly despite holding 6.4M in liquidity, with no clear path to profitability and deteriorating operational performance.
bioAffinity Technologies shows very weak fundamentals: revenue declined sharply year over year, gross margin is extremely thin at 3.9%, and losses remain far larger than revenue. While the balance sheet has no long-term debt and current liquidity is acceptable, the business is consuming cash rapidly, which makes the current growth profile low quality and likely dependent on external financing if operating performance does not improve materially.
bioAffinity Technologies, Inc. Key Strengths (BIAFW)
- Positive current ratio of 2.60x indicates short-term liquidity to fund operations
- Zero long-term debt reduces financial leverage risk
- Cash position of 6.4M provides runway for operations
- Debt-free balance sheet with no meaningful leverage pressure
- Cash balance of $6.45M and current ratio of 2.60x provide near-term liquidity support
- Net loss improved year over year, indicating some reduction in loss intensity
BIAFW Stock Risks: bioAffinity Technologies, Inc. Investment Risks
- Revenue declining sharply at -34.2% YoY indicating loss of market traction or customer base
- Negative free cash flow of -9.4M with burn rate unsustainable; cash will deplete in 6-8 quarters at current burn
- Gross margin of only 3.9% shows inability to achieve unit economics or scale efficiency
- Operating loss of -10.6M on 6.2M revenue demonstrates fundamental business model dysfunction
- No insider buying activity over 90 days suggests management lacks confidence in turnaround
- Net margin of -242% indicates company loses $2.42 for every dollar of revenue
- Revenue fell 34.2% year over year, signaling weak demand or poor commercial execution
- Gross, operating, and net margins are deeply unfavorable, showing the core business is not economically viable at current scale
- Free cash flow of negative $9.39M implies a short cash runway and elevated dilution or financing risk
Key Metrics to Watch
- Quarterly revenue trend and customer retention rates
- Operating cash flow trajectory and monthly burn rate
- Gross margin improvement and cost structure efficiency
- Cash runway remaining and path to cash flow breakeven
- Product pipeline and commercial traction metrics
- Revenue growth and gross margin improvement
- Operating cash burn relative to cash on hand
bioAffinity Technologies, Inc. (BIAFW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.60x current ratio provides a solid financial cushion.
BIAFW Profit Margin, ROE & Profitability Analysis
BIAFW vs Healthcare Sector: How bioAffinity Technologies, Inc. Compares
How bioAffinity Technologies, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is bioAffinity Technologies, Inc. Stock Overvalued? BIAFW Valuation Analysis 2026
Based on fundamental analysis, bioAffinity Technologies, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
bioAffinity Technologies, Inc. Balance Sheet: BIAFW Debt, Cash & Liquidity
BIAFW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: bioAffinity Technologies, Inc.'s revenue has grown significantly by 194,820% over the 5-year period, indicating strong business expansion. The most recent EPS of $-22.50 indicates the company is currently unprofitable.
BIAFW Revenue Growth, EPS Growth & YoY Performance
BIAFW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.4M | -$2.7M | $-0.81 |
| Q3 2025 | $1.4M | -$2.0M | $-4.74 |
| Q2 2025 | $1.3M | -$2.1M | $-0.17 |
| Q1 2025 | $1.9M | -$2.0M | $-0.16 |
| Q3 2024 | $298.5K | -$2.0M | $-0.16 |
| Q2 2024 | $19.7K | -$1.7M | $-0.19 |
| Q1 2024 | $921 | -$1.5M | $-0.18 |
| Q3 2023 | $1.2K | -$2.3M | $-0.26 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
bioAffinity Technologies, Inc. Dividends, Buybacks & Capital Allocation
BIAFW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for bioAffinity Technologies, Inc. (CIK: 0001712762)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIAFW
What is the AI rating for BIAFW?
bioAffinity Technologies, Inc. (BIAFW) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIAFW's key strengths?
Claude: Positive current ratio of 2.60x indicates short-term liquidity to fund operations. Zero long-term debt reduces financial leverage risk. ChatGPT: Debt-free balance sheet with no meaningful leverage pressure. Cash balance of $6.45M and current ratio of 2.60x provide near-term liquidity support.
What are the risks of investing in BIAFW?
Claude: Revenue declining sharply at -34.2% YoY indicating loss of market traction or customer base. Negative free cash flow of -9.4M with burn rate unsustainable; cash will deplete in 6-8 quarters at current burn. ChatGPT: Revenue fell 34.2% year over year, signaling weak demand or poor commercial execution. Gross, operating, and net margins are deeply unfavorable, showing the core business is not economically viable at current scale.
What is BIAFW's revenue and growth?
bioAffinity Technologies, Inc. reported revenue of $6.2M.
Does BIAFW pay dividends?
bioAffinity Technologies, Inc. does not currently pay dividends.
Where can I find BIAFW SEC filings?
Official SEC filings for bioAffinity Technologies, Inc. (CIK: 0001712762) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIAFW's EPS?
bioAffinity Technologies, Inc. has a diluted EPS of $-8.66.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BIAFW's fundamental grade?
Based on our AI fundamental analysis in June 2026, bioAffinity Technologies, Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BIAFW stock overvalued or undervalued?
Valuation metrics for BIAFW: ROE of -204.9% (sector avg: 15%), net margin of -242.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BIAFW's AI grade for 2026?
Our dual AI analysis gives bioAffinity Technologies, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BIAFW's free cash flow?
bioAffinity Technologies, Inc.'s operating cash flow is $-9.3M, with capital expenditures of $60.6K. FCF margin is -152.4%.
How does BIAFW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -242.0% (avg: 12%), ROE -204.9% (avg: 15%), current ratio 2.60 (avg: 2).